Age and Sex Have No Impact on Expression Levels of Markers of Immune Cell Infiltration and Immune Checkpoint Pathways in Patients with Muscle-invasive Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy
Overview
Oncology
Pharmacology
Authors
Affiliations
Objectives: Advanced age and female sex have been associated with worse outcomes in patients undergoing radical cystectomy for muscle-invasive bladder cancer. A reduced immune response has been implicated as a mechanism. The objective of our study was to analyze the expression patterns of various cellular proteins active in bladder cancer immune pathways, and assess the correlation between age, sex, and the expression of these immune markers.
Methods: We obtained surgical tissue samples from equally distributed male/female patients with/without lymph node metastasis who had undergone radical cystectomy for urothelial carcinoma (UC) of the bladder (n = 50). Immunohistochemistry (IHC) for CD3 (cluster of differentiation), CD4, CD8, CD56, LAG-3 (lymphocyte-activation gene), TIM-3 (T-cell immunoglobulin and mucin-domain), PD-1 (programmed death) and PD-L1 molecules was performed and scored by a single pathologist (high versus low). Spearman's correlation and Chi square tests investigated the association between age, sex, and IHC results.
Results: Mean age at surgery was 67 years (range 50-78 years); all patients were Caucasians. The following percent of patients scored high for a stain: 18% CD3, 10% CD4, 0% CD8, 0% CD56, 20% LAG-3, 4% TIM-3, 0% PD-1 and 0% PD-L1. There was no association between patients' age, sex, and the expression of any of the immune markers (p > 0.05 for all).
Conclusions: The association between advanced age, female sex, and worse outcomes in bladder cancer may be independent of the immune pathways active in the disease that we examined in this study.
PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer.
Fan Y, Dai T, Zhang D, Guo H, Zhou F, Shi B Sci Rep. 2024; 14(1):16753.
PMID: 39033240 PMC: 11271459. DOI: 10.1038/s41598-024-67508-6.
Plage H, Furlano K, Hofbauer S, Weinberger S, Ralla B, Franz A BMC Urol. 2024; 24(1):96.
PMID: 38658905 PMC: 11041044. DOI: 10.1186/s12894-024-01482-z.
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas.
Kumar U, Anthony M, Sahai R, Mittal A, Durgapal P, Kishore S J Lab Physicians. 2022; 14(2):197-201.
PMID: 35982880 PMC: 9381309. DOI: 10.1055/s-0041-1736480.
Bladder cancer, inflammageing and microbiomes.
Martin A, Woolbright B, Umar S, Ingersoll M, Taylor 3rd J Nat Rev Urol. 2022; 19(8):495-509.
PMID: 35798831 DOI: 10.1038/s41585-022-00611-3.
Chung J, Lee C, Lee D, Song W Biomedicines. 2022; 10(4).
PMID: 35453659 PMC: 9029191. DOI: 10.3390/biomedicines10040910.